We therefore conclude that other pathways such as the Wnt signalling pathway or RAS/RAF/MEK/MAPK signalling pathway may be involved in MPNST drug resistance during the treatment with AKT and mTOR inhibitors. This evidence concerns the gene MTOR and malignant peripheral nerve sheath tumor.